U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Refractory Malignant Female Reproductive System Neoplasm

MedGen UID:
1791634
•Concept ID:
C5555193
•
Neoplastic Process

Definition

A malignant female reproductive system neoplasm that progresses during platinum therapy or within one month of completing the last platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Refractory Malignant Female Reproductive System Neoplasm

Professional guidelines

PubMed

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM
Med Oncol 2017 Jun;34(6):103. Epub 2017 Apr 25 doi: 10.1007/s12032-017-0960-z. PMID: 28444622
Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M, Kolesar J
Am J Health Syst Pharm 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550. PMID: 27385701

Recent clinical studies

Etiology

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I
Crit Rev Oncol Hematol 2006 Nov;60(2):159-79. Epub 2006 Oct 2 doi: 10.1016/j.critrevonc.2006.03.004. PMID: 17018256
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M, Blessing JA, Moore D, Ball H, Lentz SS
Gynecol Oncol 1998 Jun;69(3):226-9. doi: 10.1006/gyno.1998.5016. PMID: 9648592
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M
J Clin Oncol 1992 Sep;10(9):1485-91. doi: 10.1200/JCO.1992.10.9.1485. PMID: 1355523

Diagnosis

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM
Med Oncol 2017 Jun;34(6):103. Epub 2017 Apr 25 doi: 10.1007/s12032-017-0960-z. PMID: 28444622
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I
Crit Rev Oncol Hematol 2006 Nov;60(2):159-79. Epub 2006 Oct 2 doi: 10.1016/j.critrevonc.2006.03.004. PMID: 17018256

Therapy

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I
Crit Rev Oncol Hematol 2006 Nov;60(2):159-79. Epub 2006 Oct 2 doi: 10.1016/j.critrevonc.2006.03.004. PMID: 17018256
New drugs in gynecologic cancer.
Daud A, Munster P, Munster P, Spriggs DR
Curr Treat Options Oncol 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. PMID: 12057130

Prognosis

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I
Crit Rev Oncol Hematol 2006 Nov;60(2):159-79. Epub 2006 Oct 2 doi: 10.1016/j.critrevonc.2006.03.004. PMID: 17018256
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janát MM, Untch M, Konecny G, Bruckner HW, Cree IA
Recent Results Cancer Res 2003;161:221-30. doi: 10.1007/978-3-642-19022-3_17. PMID: 12528810
New drugs in gynecologic cancer.
Daud A, Munster P, Munster P, Spriggs DR
Curr Treat Options Oncol 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. PMID: 12057130

Clinical prediction guides

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA
J Clin Oncol 2024 Dec 20;42(36):4305-4316. Epub 2024 Oct 3 doi: 10.1200/JCO.24.00683. PMID: 39361946Free PMC Article
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
González-Martín A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z
Gynecol Oncol 2024 Jul;186:182-190. Epub 2024 May 7 doi: 10.1016/j.ygyno.2024.04.011. PMID: 38718741
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M, Giorda G, Viel A, Fornasarig M, Zdjelar A, Segatto E, Sorio R, Corsetti S, Scalone S, Nicoloso MS, Pivetta T, Lucia E, Clemente N, Palazzari E, Canzonieri V, Puglisi F
Curr Oncol 2022 Jul 22;29(8):5209-5212. doi: 10.3390/curroncol29080413. PMID: 35892982Free PMC Article
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631

Recent systematic reviews

Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer.
Martorana F, Pavone G, Sessa C, Treglia G, Lheureux S, Colombo I
Int J Gynecol Cancer 2025 Jan;35(1):100009. Epub 2024 Dec 17 doi: 10.1016/j.ijgc.2024.100009. PMID: 39878268
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R, Seshadri S, Montes A, Lane G
Cochrane Database Syst Rev 2016 Jun 29;2016(6):CD011322. doi: 10.1002/14651858.CD011322.pub2. PMID: 27356090Free PMC Article
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R
Health Technol Assess 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090. PMID: 16545208

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...